{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.04","upperLimit":"24.36","value":"10.90"},{"groupId":"OG001","lowerLimit":"7.93","upperLimit":"20.50","value":"11.60"},{"groupId":"OG002","lowerLimit":"7.96","upperLimit":"16.61","value":"10.33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Topotecan plasma concentration-time data are collected on day 1 of maintenance cycle A1 after a single oral dose. Individual estimates of topotecan AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.","dispersionType":"Full Range","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG002","title":"High-Risk Group"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who received oral topotecan during maintenance therapy cycle A1 and had samples collected for PK analysis.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 1.5, 6, and 24 hours post-dose","title":"Topotecan AUC0-24h in Maintenance Chemotherapy","type":"SECONDARY","unitOfMeasure":"µg·h/L"}